M. SueO'DorisioMDPhD

Pediatric Neuro-Oncology, Pediatric Solid Tumor Oncology

Professor of Pediatrics

Dr. O'Dorisio is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
200 Hawkins Drive
Iowa City, IA 52242
Phone+1 319-356-3595

Fax+1 319-356-7659

I am a board certified pediatric hematologist/oncologist with expertise in the diagnosis and care of children with neuroendocrine tumors, neuroblastoma, and pheochromocytoma/paraganglioma. I specialize in treatment of children with theranostics, using beta emitting and alpha emitting radionuclides.

Lifetime Achievement Award North American Neuroendocrine Tumor Society, 2017
Distinguished Mentor Award University of Iowa Carver College of Medicine, 2015
North American Delegate International Atomic Energy Agency of United Nations, 2009
Ohio Wesleyan Honorary Doctor of Science Degree 2000
Alumni Achievement Citation Creighton University, 1999
American Academy Peds Award Pediatric Research, 1998
Distinguished Scholar Award The Ohio State University, 1998
R & E Ross Chair Pediatric Cancer Research, 1997
Research Mentor Award Ohio State University, 1995
Woman of Achievement Award YWCA, 1989
Emmerich Von Haam Research Award 1985
Alpha Omega Alpha 1984
Join now to see all

PubMed

9 citations
VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.
Catalina Abad, Bhavaani Jayaram, Laurine Becquet, Yuqi Wang, M Sue O'Dorisio
Journal of Neuroinflammation. 2016-06-29
54 citations
Technical Note: Single time point dose estimate for exponential clearance.
Mark T. Madsen, Yusuf Menda, Thomas M. O'Dorisio, M. Sue O'Dorisio
Medical Physics. 2018-05-01
10 citations
Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors.
David L. Bushnell, Kellie L. Bodeker, Thomas M. O'Dorisio, Mark T. Madsen, Yusuf Menda
Journal of Nuclear Medicine. 2021-01-30

Journal Articles

Pancreastatin Predicts Survival in Neuroendocrine Tumors
Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR, Ann Surg Oncol, 4/22/2014
GIPR Expression in Gastric and Duodenal Neuroendocrine Tumors
Sherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR, Journal of Surgical Research, 1/1/2014
Gastric Inhibitory Polypeptide Receptor (GIPR) Is a Promising Target for Imaging and Therapy in Neuroendocrine Tumors
Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR, Surgery., 12/1/2013
Repeatability of Gallium-68 DOTATOC Positron Emission Tomographic Imaging in Neuroendocrine Tumors
Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, Madsen MT, Sunderland JJ, Graham MM, O'Dorisio TM, O'Dorisio MS, Pancreas, 1/1/2013
G-protein Coupled Receptor Expression Patterns Delineate Medulloblastoma Subgroups
Whittier KL, Boese EA, Gibson-Corley KN, Kirby PA, Darbro BW, Qian Q, Ingram WJ, Robertson T, Remke M, Taylor MD, O'Dorisio MS, Acta Neuropathol Commun., 1/1/2013
Neuroendocrine Tumors in Children and Young Adults: Rare or Not so Rare?
Sarvida ME, O'Dorisio MS, Endocrinol Metab Clin North Am, 1/1/2011
Characterization of Intestinal and Pancreatic Dysfunction in VPAC1-null Mutant Mouse
Fabricius D, Karacay B, Shutt D, Leverich W, Schafer B, Takle E, Thedens D, Khanna G, Raikwar S, Yang B, Desmond M and O'Dorisio MS, Pancreas, 1/1/2011
Join now to see all